Zentalis Pharmaceuticals (ZNTL)

• Market cap: $91.9M
• 1 day: -5.88%
• 5 days: -26.86%
• 1 month: -33.33%
• 3 months: -60.49%
• 6 months: -60.00%
• Year to date: -57.33%
• 1 year: -91.81%
• 5 years: -94.48%
• 10 years: -94.48%
• Sector: Healthcare
• Industry: Biotechnology

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

84% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 31

38% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 24

4% more funds holding

Funds holding: 136 [Q3] → 142 (+6) [Q4]

3% more call options, than puts

Call options by funds: $229K | Put options by funds: $222K

10.1% less ownership

Funds ownership: 100.48% [Q3] → 90.39% (-10.1%) [Q4]

26% less capital invested

Capital invested by funds: $263M [Q3] → $195M (-$67.8M) [Q4]

67% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.20 72% upside
• Avg. target: $5.55 334% upside
• High target: $10 681% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Wedbush Robert Driscoll 4% 1-year accuracy 2 / 47 met price target	213% upside $4	Neutral Reiterated	28 Mar 2025
HC Wainwright & Co. Andrew Fein 28% 1-year accuracy 102 / 358 met price target	681% upside $10	Buy Reiterated	27 Mar 2025
Wells Fargo Derek Archila 39% 1-year accuracy 12 / 31 met price target	369% upside $6	Equal-Weight Maintained	30 Jan 2025
UBS Eliana Merle 31% 1-year accuracy 5 / 16 met price target	72% upside $2.20	Neutral Maintained	28 Jan 2025